| Autor: |
Frei, Christopher Raymond, Ryan, Kellie, Obodozie-Ofoegbu, Grace Oby, Moore, Amanda Marie, Teng, Chengwen, Lucero, Kana Tai, Davis, Laura Dean, Jones, Xavier Francisco, Nooruddin, Zohra |
| Předmět: |
|
| Zdroj: |
Leukemia & Lymphoma; Oct2024, Vol. 65 Issue 10, p1520-1523, 4p |
| Abstrakt: |
This document discusses the shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL). CLL is a manageable but incurable condition, and a watch-and-wait approach is often used for asymptomatic patients. However, for patients requiring treatment, targeted therapies have revolutionized the treatment landscape. This study analyzed data from the VA system and found that the use of targeted therapies has increased over time, surpassing traditional chemotherapy/chemoimmunotherapy. Specifically, the use of ibrutinib accounted for the greatest proportion of targeted therapy use, followed by venetoclax and acalabrutinib. The study highlights the importance of understanding treatment patterns and the impact of targeted therapies in CLL management. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
